General MedicationsTOPICALStandard
WYNZORA
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE
Standard Dose
0.064%;0.005%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview WYNZORA is listed in Drugs@FDA under application 213422 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE Form and strength CREAM;TOPICAL - 0.064%;0.005% Sponsor MC2 Submission history Latest submission status date: 2020-07-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview WYNZORA is listed in Drugs@FDA under application 213422 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE Form and strength CREAM;TOPICAL - 0.064%;0.005% Sponsor MC2 Submission history Latest submission status date: 2020-07-20 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.